We have previously shown that BALB/c antipneumococcal polysaccharide antibodies with phosphorylcholine (PC) specificity are self-binding, mediated by hypervariable sequence structure of the heavy chain. We extended the observation of self-binding anti-PC antibodies to naturally occurring human anti-PC antibodies. Anti-PC antibodies were purified from normal donor sera and shown to bind to monoclonal antiidiotypic anti-T15 antibodies originally raised against the murine T15 idiotype. These human antibodies are self-binding which is inhibitable by the PC hapten and the murine T15 (50-73)-derived Vh peptide. The anti-PC antibodies were further separated into id-positive and id-negative anti-PC antibodies. Only the T15 id-positive preparation was self-binding. These findings demonstrate an evolutionary, conserved biological property between mouse and man associated with a naturally occurring antibacterial antibody. This conserved biological and structural property may have been selected in evolution because it is part of an important immune defense mechanism against bacterial and other environmental pathogens. (J. Clin. Invest. 1991. 88:476482.)
Analogously, the antipneumococcal response in humans involves the PC epitope since it has been observed (10) that the anti-PC titers are increased in children who have recovered from pneumococcal infections. Other investigators have also identified human phosphorylcholine-binding immunoglobulins (11) . However, these authors did not identify a dominant idiotype associated with the anti-PC antibodies nor did they demonstrate a mouse-man idiotypic cross-reactivity.
Self-binding antibodies, termed "autobodies," have previously been described (12) . These antibodies belong to the group of germline encoded immunoglobulins of the murine S 107/TEPC (T 15) V 1 gene (1 3). The self-binding site is located near the PC binding site ofthese antibodies and involves structures of the hypervariable region of the heavy chain. Recently, we have shown that a 24-residue peptide spanning the heavy chain ofT 15 was nearly as effective as the hapten PC in inhibiting the self-binding complexes (14) .
Because anti-PC antibodies are important for protection against bacterial infection mediated by anti-PC antibodies in man, we wanted to investigate the human repertoire ofanti-PC antibodies. In particular, we were interested to see if self-binding antibodies occur in human sera and whether such antibodies are PC-specific. We isolated anti-PC antibodies from human sera and could demonstrate that these antibodies selfbind. Using an anti-Tl 5 mAb, F6, we were able to show that human anti-PC self-binding antibodies express the murine T 15 idiotype. From these findings, we tested whether the CDR2/ FR3 sequence ofmurine T 15 (S 107/V 1) is critical for self-complexing ofhuman anti-PC antibodies and present evidence that a peptide derived from the CDR2/FR3 region of the heavy chain of murine T 15 can inhibit the self-complexing ofhuman anti-PC antibodies. This finding demonstrates that very similar structures of the VH region in mouse and man are mediating self-binding.
The discovery of a conserved self-binding site between mouse and man anti-PC antibodies is compelling evidence for a functional role of self-binding in protective immune re- sponses.
Methods
Sera. Human sera were purchased from the San Diego Blood Bank, randomly selected. BALB/c sera were obtained from mice in our colony; CBA/N serum was a kind gift from Ann Feeny, Medical Biology Institute, La Jolla, CA.
Antibodies and peptides. Myeloma cell lines T15 and M167 were obtained from Litton Bionetics, Kensington, MD, and purified from ascites fluid by a PC-Sepharose column. The 1 1E7 hybridoma has been described previously (2) . F6, an anti-T15, is described (8). AB1.2 and B39 anti-T 15 antibodies were kind gifts ofJohn Kearney, University of Alabama, Birmingham.
The peptides T15H (50-73) (ASRNKANDYTTEYSASVKGR-FIVS) (14) , 2F10 (50-73) (QIPGDGDTKYNNGKFKGKATLT) (15) used in this study were synthesized as previously described (14) .
Purification To measure the binding of human Ig to antiidiotype, F6, B39, and AB 1.2 plates were coated with 2 mg/ml ofrespective anti-ids, dilutions ofpurified human antibodies were added, and after washing, goat antihuman IgG and IgM peroxidase (Fisher) was added (1:1,000 diluted). Color was read as described above.
To measure self-binding of purified human anti-PC antibodies, plates were coated with purified human anti-PC antibodies, 5 ,g/ml for 16 h at 4VC. Biotinylated human anti-PC antibodies were added (1:50 diluted) and the plates were incubated for 16 h at 4VC. After washing, peroxidase-conjugated avidin (Fisher) was added (1:1,000 diluted), and color was read as described above.
The inhibition ofself-binding ofthe human anti-PC antibodies was demonstrated by coincubating biotinylated antibodies with increasing amounts of PC or VH (50-73) derived peptide as described above.
RIA. To quantify the T15 equivalents in human sera with regard to PC and anti-T1 5 titers a RIA was used. Plates were coated with PC-BSA or F6 (5 ,ug/ml) for 16 h at 4°C. After washing, dilutions ofhuman sera were coincubated with '251-labeled T15 (100,000 cpm) for 16 h at 4°C. After extensive washing the bound radioactivity in each well was measured in a gamma counter. T 15 equivalents were calculated using as standard the inhibition of these assays by unlabeled T1 5.
Self-binding was revealed by adding 251I-labeled murine and human antibodies (100,000 cpm/well) to plates coated with 5 jug/ml of 1 1E7, M167, human purified anti-PC antibodies, and human anti-Tg antibodies for 16 h at 40C. After extensive washing the bound radioactivity was measured in a gamma counter. For inhibition experiments, 125I-labeled antibodies were coincubated with inhibitors of self-binding, PC, and VH (50-73) derived peptide at varying concentrations for 16 h at4°C.
Results
L Characterization and purification ofhuman anti-PC antibodies Anti-PC antibodies in human sera. Gray and co-workers (10) have previously reported the presence ofanti-PC antibodies in infants who have recovered from streptococcic infections. In addition, Stein and Sigal (16) human sera contain antibodies that bind to the anti-Ti5 F6 monoclonal antibody.
It is noteworthy that several sera contain more anti-PC antibodies than anti-T1 5 positive antibodies. We also measured the T15 equivalents using other antiidiotype reagents, Abl.2 and B39. As control for anti-Id binding a murine IgGI, kappa anti-Id, specific for human anti-HIV envelope antibodies (Muller et al., submitted for publication) was used. No binding to 2A II was observed (Fig. 3 d) . We found that using these anti-T1 5 antibodies, human sera contained T1 5 equivalent values several-fold less than detected by F6 (data not shown).
Purification ofhuman anti-PC antibodies. Anti-PC antibodies in mouse sera are of IgM and IgG subclasses. Therefore, we aimed to isolate human anti-PC antibodies of both isotypes. The ammonium sulfate-precipitated Ig of several human sera were chromatographed on Sephacryl 300HR. Fractions were analyzed for binding to insolubilized PC-BSA. Bound antibodies were assayed with goat peroxidase-conjugated anti-human IgM and IgG antisera. A representative elution profile from a single donor serum is shown in Fig. 2 . The data indicate the presence of anti-PC antibodies of IgM and IgG classes eluting at the expected high and low molecular weight positions, respectively. The corresponding fractions were pooled.
The separated IgM and IgG anti-PC pools were then applied to PC-Sepharose immunoabsorbent and binding antibodies were eluted by IO-' M PC according to (18) . The purity of IgM and IgG anti-PC antibodies purified from three different sera was analyzed by SDS-PAGE (data not shown). The purity of both preparations was estimated to be > 90%.
Characterization of human anti-PC antibodies. The puri- preparations, the IgM and IgG anti-PC antibodies, were completely inhibited by PC (50% inhibition for IgG achieved by 5
x IO-' M PC, for IgM by 2 X 10-4 M PC). These values are in the range needed for inhibiting the IgM anti-PC hybridoma 1 1E7 (IgM, kappa) ( 12). Next we asked whether anti-PC antibodies bind to antiidiotype antibodies against the mouse T1 5 idiotype. Purified anti-PC were added to anti-id coated plates, F6, Abi .2, or B39. Bound human antibodies were detected by enzyme-labeled goat anti-human IgM and IgG. As representative example the data on anti-PC antibodies from one donor are shown in Fig. 3 . Both IgM and IgG human anti-PC antibodies bind all three anti-Ids with different degrees. Individual variations ofbinding were observed with anti-PC antibodies purified from different donors. This indicates that the three antimurine anti-T15 antiidiotypic antibodies cross-react with human anti-PC antibodies demonstrating that human and murine anti-PC antibodies share idiotopes. II. Self-binding ofhuman anti-PC antibodies Human anti-PC antibodies are self-binding. We have previously shown that murine anti-PC antibodies have the unique property ofself-binding (12) (13) (14) . Here we investigated whether purified total, i.e., not separated into IgG and IgM, human anti-PC antibodies, purified from pooled human serum on PCSepharose, have self-binding activity. As seen in Fig. 4 A, selfbinding is demonstrated by plates coated with purified human anti-PC antibody and incubated with "25I-labeled human anti-PC antibody. As controls are shown: the T 15 negative murine anti-PC antibody M167, a purified human antithyroglobulin which does not self-bind, and 1 IE7 (T15+, IgM,k) which strongly self-binds (12) .
Next, the specificity of self-binding was analyzed by hapten inhibition. Plates were coated with mouse or total purified human anti-PC antibody or human antithyroglobulin antibody and incubated with 125"-labeled mouse or human anti-PC antibody or human antithyroglobulin antibody in the presence of various concentrations of PC. As seen in Fig. 4 B, PC specifically inhibited the self-binding. Recently (14), we reported the inhibition of murine self-binding anti-PC antibodies by a VHderived peptide spanning residues 50-73 in T15 and demonstrated the importance of this region in murine anti-PC self- the peptide 2F10 VH(50-73), derived from the heavy chain of an unrelated antibody, had no effect on self-binding.
III. Characterization ofhuman IgG and IgM anti-PC antibodies
The separated IgM and IgG anti-PC antibodies described in bound radioactivity was measured in a gamma PC [ M0I ] counter.
tions from several donors were unsuccessful. As seen in Fig. 6 , a and b, the human IgG anti-PC antibodies did not self-bind. This failure could be due to the intrinsic low self-binding property of 7S immunoglobulin observed earlier with murine IgG T15+ anti-PC hybridoma (12) . The results with purified human anti-PC antibodies demonstrate that these antibodies are indeed self-binding in similar fashion as the murine counterpart.
IV. Further characterization ofself-binding antibodies
The finding that human anti-PC antibodies self-bind and express the T1 5 idiotype led us to ask whether the self-binding property of human anti-PC antibodies is dependent on the expression of the cross-species reactive T1 5 idiotype. To address this question pooled normal Ig were sequentially purified on PC-Sepharose and F6-Sepharose immunoabsorbents. This scheme produced anti-PC antibodies which are either T.15 positive or T1 5 negative (see Fig. 7 ). Ammonium sulfate-purified Ig was affinity purified on an F6-Sepharose immunoabsorbent by elution with acid (data not shown). The eluted material was neutralized, concentrated, To confirm that the self-binding ofhuman anti-PC antibodies is associated with the expression of the T1 5 idiotype we reversed the order of sequential purification on PC and F6-Sepharose immunoabsorbents. Ammonium sulfate-precipitated human pooled Ig was first purified on PC-Sepharose and eluted material was passed over F6-Sepharose (see left-hand side ofFig. 7). Material bound to F6-Sepharose was eluted with acid buffer. The eluted material was neutralized and concentrated. Both the flow through and eluted material from the F6-Sepharose column were biotinylated and assayed for selfbinding on solid phase. Fig. 9 shows that the F6+PC+, but not the F6-PC+ human Ig, is self-binding and that this self-binding is inhibited by free PC. Fig. 9 
Discussion
The key finding in this study is that in normal human sera anti-PC antibodies exist that cross-react with murine anti-PC antibodies of the T15 idiotype. Three monoclonal anti-T15 antibodies, one ofwhich detects an idiotope associated with the PC binding site (8) , react with immunoglobulins in sera ofnormal human donors. Anti-PC antibodies were purified from human sera and tested for hapten specificity and binding to anti-T1 5 antiidiotypic antibodies. The monoclonal anti-T1 5 antibodies show binding to affinity purified human anti-PC antibodies of IgM and IgG isotypes. One of the hallmarks of murine anti-PC antibodies of the T1 5 idiotype is the property of self-binding or specific self-associating (12) (13) (14) . The purified human anti-PC antibodies share this property with the murine counterpart. Like mouse T1 5 positive anti-PC antibodies, human anti-PC antibodies show self-binding. The self-binding of human antibody is like the mouse antibody inhibited by the hapten PC, indicating the involvement ofthe PC binding site in self-binding. Furthermore, a 22-mer peptide derived from the CR2-FR3 region of the mouse T1 5 heavy chain inhibits human self-binding. The degree ofsimilarity ofself-binding structures ofhuman and murine self-binding antibodies cannot, at this time, be determined because we do not know the sequence ofhuman selfbinding antibodies. We searched the sequence data base on human immunoglobulins for homology with the T 15 VH (50-73) region and did not find significant sequence similarities. This would imply that the primary structure responsible for self-binding antibodies can differ significantly and thus, that the conserved self-binding property is maintained in evolution by different primary structures. To further decipher the molecular basis of self-binding, Kaveri (19) has recently demonstrated the specific binding ofmouse and human antibodies to the T 1 5 H (50-73) peptide. In addition, the authors were able to isolate T1 5 H (50-73) peptide-specific antibodies from pooled normal human immunoglobulin and have shown that these peptide specific human antibodies are self-binding (19) . This further emphasizes the evolutionary conserved structure of the selfbinding locus which must be similar in mouse and man.
An important question is whether self-binding of human antibodies is restricted to the T1 5 id, like in the BALB/c mouse. To address this question we isolated anti-PC antibodies that were T1 5 id+ or T1 5 id-. We found that only the T15 id+ antibodies were self-binding and that the self-binding is inhibited by the hapten PC and the T1 5 VH-derived peptide. Since the molarity ofPC giving 50% inhibition ofmurine and human self-binding antibodies is similar the structures involved in selfbinding are likely to be similar. Therefore, it is of interest to know to what extent the common biological self-binding potential is based on similar structures.
The finding ofa conserved interspecies idiotype that is associated with an antibacterial response suggests that the T1 5 id may be maintained in evolution because it is fundamental to survival. In the mouse, Ti 5-positive anti-PC antibodies have been shown to be the most effective antibodies for protection against pneumococcal infection (7) . Conserved interspecies idiotypes have also been reported for influenza (20) and hepatitis (21) emphasizing the importance of maintaining certain Vregion genes in the immune repertoire. In this report we add to a list of functional characteristics of antibodies the property of self-binding as one of the biological functions conserved between mice and human anti-PC antibodies. We speculate that self-binding as part of the protective antibacterial response in two divergent species may have an important role in the regulation of the immune response against infectious agents.
Finally, we do not understand the clonal selection pathways by which B cells producing self-binding antibodies emerge dominant during development of the immune system and whether these processes continue during the ongoing adaptation to environmental and infectious challenges throughout the life of the individual.
